Promises and pitfalls of oral cancer chemotherapy

Clinical Advances in Hematology and Oncology

Volumn 7, Issue 2 SUPPL. 4, 2009, Pages 8-10

  Egorin, Merrill J ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOCHROME P450; DASATINIB; IMATINIB; LAPATINIB; NILOTINIB; PROTON PUMP INHIBITOR;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; COST BENEFIT ANALYSIS; DIETARY FIBER; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG METABOLISM; DRUG PACKAGING; DRUG USE; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HUMAN; INJECTION SITE IRRITATION; LIPID DIET; PATIENT COMPLIANCE; PATIENT EDUCATION; PRESCRIPTION; QT PROLONGATION; SIDE EFFECT; TREATMENT REFUSAL;

EID: 66749166436     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
2. Bristol-Myers Squibb. Sprycel prescribing information. Available at http://pack-ageinserts.bms.com/pi/pi_sprycel.pdf.
3. Sparano BA, Egorin MJ, Parise RA, et al. Effect of antacid on imatinib absorption. Cancer Chemother Pharmacol. 2009;63:525-528.
4. Aschenbrenner DS. Advances in Cancer Therapy. Am J Nurs. 2008;108:50-51.
5. Deremer DL, Ustun C, Natarajan K. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther. 2008;30:1956-1975.
6. Rahman A, Pazdur R, Wang Y, Huang SM, Lesko L. The value meal: effect of food on lapatinib bioavailability. J Clin Oncol. 2007;25:5333-4; author reply 4-5.
7. Davis TC, Federman AD, Bass PF, 3rd, et al. Improving patient understanding of prescription drug label instructions. J Gen Intern Med. 2009;24:57-62.
8. Wolf MS, Davis TC, Shrank W, et al. To err is human: patient misinterpretations of prescription drug label instructions. Patient Educ Couns. 2007;67:293-300.
9. IOM (Institute of Medicine). 2008. Standardizing medication labels: Confusing patients less, workshop summary. Washington, DC: The National Academies Press
10. McLeod HL, Evans WE. Oral cancer chemotherapy: the promise and the pitfalls. Clin Cancer Res. 1999;5:2669-2671.
11. Lebovits AH, Strain JJ, Schleifer SJ, Tanaka JS, Bhardwaj S, Messe MR. Patient noncompliance with self-administered chemotherapy. Cancer. 1990;65:17-22.
12. Reed SD, Anstrom KJ, Ludmer JA, Glendenning GA, Schulman KA. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2004;101: 2574-2583.
13. Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics. 2007;25:481-496.
14. Feng W, Henk H, Thomas S, et al. Compliance and persistency with imatinib. Program and abstracts of the 42nd Annual Meeting of the American Society of Clinical Oncology; Atlanta, Georgia 2006; June 2-6, 2006: Abstract 6038.
15. Henk HJ, Thomas SK, Feng W, Jean-Francois B, Goldberg GA, Hatfield A. The impact of non-compliance with imatinib (IM) therapy on health care costs. Program and abstracts of the 42nd Annual Meeting of the American Society of Clinical Oncology; Atlanta, Georgia; June 2-6, 2006: Abstract 6083.
16. Perry MC. The Chemotherapy Source Book. Philadelphia: Lippincott Williams & Wilkins; 4th Ed. 2008.
17. GIST Support International. Measuring imatinib (Gleevec) blood plasma levels. Available at http://www.gistsupport.org/treatments/gleevec/ measuring-imatinib-gleevec-blood-plasma-levels.php.
18. Wright JM, Htun Y, Leong MG, Forman P, Ballard RC. Evaluation of the use of calendar blister packaging on patient compliance with STD syndromic treatment regimens. Sex Transm Dis. 1999;26:556-563.
19. Simmons D, Upjohn M, Gamble GD. Can medication packaging improve glycemic control and blood pressure in type 2 diabetes? Results from a randomized controlled trial. Diabetes Care. 2000;23:153-156.
20. Huang HY, Maguire MG, Miller ER, 3rd, Appel LJ. Impact of pill organizers and blister packs on adherence to pill taking in two vitamin supplementation trials. Am J Epidemiol. 2000;152:780-787.
21. Ringe JD, van der Geest SA, Moller G. Importance of calcium co-medication in bisphosphonate therapy of osteoporosis: an approach to improving correct intake and drug adherence. Drugs Aging. 2006;23:569-578.
22. Novartis. Tasigna prescribing information. Available at www.novartis.com.au/PI_PDF/tas.pdf
23. Tuma RS. Disease progression in some cancers may be due to low blood levels of targeted therapies. J Natl Cancer Inst. 2008; 100:912-913.